South SudanTuberculosis profile
Population  2018 11 million
Estimates of TB burdenº, 2018 Number (thousands) Rate
(per 100 000 population)
Total TB incidence 16 (10–23) 146 (95–209)
HIV-positive TB incidence 1.9 (1.2–2.8) 18 (11–25)
MDR/RR-TB incidenceºº 0.53 (0.24–0.95) 4.8 (2.1–8.6)
HIV-negative TB mortality 0.93 (0.46–1.6) 8.4 (4.2–14)
HIV-positive TB mortality 0.25 (0.15–0.38) 2.3 (1.3–3.5)
Estimated proportion of TB cases with MDR/RR-TB, 2018
New cases 2.4% (1.1–4.2)
Previously treated cases 15% (11–19)
TB case notifications, 2018  
Total new and relapse 14 603
          - % tested with rapid diagnostics at time of diagnosis <1%
          - % with known HIV status 90%
          - % pulmonary 82%
          - % bacteriologically confirmedººº 59%
          - % children aged 0-14 years 18%
          - % women 30%
          - % men 52%
Total cases notified 14 964
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2018 91% (64–140)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2018 8% (4–13)
TB/HIV care in new and relapse TB patients, 2018 Number (%)
Patients with known HIV status who are HIV-positive 1 579 12%
          - on antiretroviral therapy 1 471 93%
Drug-resistant TB care, 2018
% of bacteriologically confirmed TB cases tested for rifampicin resistance ººº
          - New cases <1%
          - Previously treated cases 15%
Laboratory-confirmed cases* MDR/RR-TB: 53, XDR-TB: 0
Patients started on treatment* ** MDR/RR-TB: 28, XDR-TB: 0
MDR/RR-TB cases tested for resistance to second-line drugs  
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2017    
Previously treated cases, excluding relapse, registered in 2017    
HIV-positive TB cases registered in 2017    
MDR/RR-TB cases started on second-line treatment in 2016   0
XDR-TB cases started on second-line treatment in 2016   0
TB preventive treatment, 2018  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2019  
National TB budget (US$ millions) 12
Funding source:  domestic, 34% international, 66% unfunded
º Ranges represent uncertainty intervals
ºº MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
ººº Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Incidence graph
   Total TB incidence
   New and relapse TB cases notified
   HIV-positive TB incidence

(Rate per 100 000 population per year)
Mortality graph
   HIV-negative TB mortality

Notified cases by age group and sex, 2018
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2019-10-22 Data: www.who.int/tb/data